Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
West Nile Virus Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, ‘West Nile Virus Infections - Pipeline Review, H1 2016', provides an overview of the West Nile Virus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for West Nile Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections - The report reviews pipeline therapeutics for West Nile Virus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved West Nile Virus Infections therapeutics and enlists all their major and minor projects - The report assesses West Nile Virus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for West Nile Virus Infections Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 West Nile Virus Infections Overview 7 Therapeutics Development 8 Pipeline Products for West Nile Virus Infections - Overview 8 Pipeline Products for West Nile Virus Infections - Comparative Analysis 9 West Nile Virus Infections - Therapeutics under Development by Companies 10 West Nile Virus Infections - Therapeutics under Investigation by Universities/Institutes 11 West Nile Virus Infections - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 West Nile Virus Infections - Products under Development by Companies 14 West Nile Virus Infections - Products under Investigation by Universities/Institutes 15 West Nile Virus Infections - Companies Involved in Therapeutics Development 16 BioDiem Ltd 16 CalAsia Pharmaceuticals, Inc. 17 CEL-SCI Corporation 18 Kineta, Inc. 19 Nanotherapeutics, Inc. 20 West Nile Virus Infections - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 BG-323 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 CEL-1000 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 FDX-000 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 HydroVax-001 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 KIN-1148 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Monoclonal Antibody for West Nile Virus Infections - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 RL-14C - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 RL-15A - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Small Molecule to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules to Agonize IRF-3 for Viral Infections - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Synthetic Peptide for Dengue Virus and West Nile Virus Infections - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 West Nile virus vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 West Nile virus vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 West Nile virus vaccine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 West Nile Virus Infections - Recent Pipeline Updates 48 West Nile Virus Infections - Dormant Projects 49 West Nile Virus Infections - Product Development Milestones 52 Featured News & Press Releases 52 Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials 52 Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Number of Products under Development for West Nile Virus Infections, H1 2016 8 Number of Products under Development for West Nile Virus Infections - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 West Nile Virus Infections - Pipeline by BioDiem Ltd, H1 2016 16 West Nile Virus Infections - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016 17 West Nile Virus Infections - Pipeline by CEL-SCI Corporation, H1 2016 18 West Nile Virus Infections - Pipeline by Kineta, Inc., H1 2016 19 West Nile Virus Infections - Pipeline by Nanotherapeutics, Inc., H1 2016 20 Assessment by Monotherapy Products, H1 2016 21 Number of Products by Stage and Target, H1 2016 23 Number of Products by Stage and Mechanism of Action, H1 2016 25 Number of Products by Stage and Route of Administration, H1 2016 27 Number of Products by Stage and Molecule Type, H1 2016 29 West Nile Virus Infections Therapeutics - Recent Pipeline Updates, H1 2016 48 West Nile Virus Infections - Dormant Projects, H1 2016 49 West Nile Virus Infections - Dormant Projects (Contd..1), H1 2016 50 West Nile Virus Infections - Dormant Projects (Contd..2), H1 2016 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
